[{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Merit E. Cudkowicz, MD","sponsor":"Ra Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Merit E. Cudkowicz, MD","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merit E. Cudkowicz, MD \/ Ra Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Merit E. Cudkowicz, MD \/ Ra Pharmaceuticals"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ UCB Pharma S.A","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Ghent \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"Complement C5","graph1":"Undisclosed","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Zilucoplan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 19, 2024

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 24, 2024

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Zilbrysq (zilucoplan), the first FDA-approved self-administered C5 complement inhibitor, treats generalized myasthenia gravis in anti-AChR antibody-positive adults.

                          Product Name : Zilbrysq

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 01, 2024

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Zilbrysq (zilucoplan) is a once-daily, SC, self-administered peptide inhibitor of complement component 5 (C5 inhibitor). As the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.

                          Product Name : Zilbrysq

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 17, 2023

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : RA101495 (zilucoplan) is a once-daily SC, self-administered peptide inhibitor of complement component 5, which is investigated for the treatment of adults with generalized myasthenia gravis.

                          Product Name : Zilbrysq

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          September 15, 2023

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Zilbrysq (zilucoplan) is a C5 inhibitor peptide drug candidate, which is currently being evaluated for the treatment of patients with AChR antibody-positive generalized myasthenia gravis.

                          Product Name : Zilbrysq

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 12, 2023

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Zilucoplan is a subcutaneous (SC), self-administered peptide inhibitor of complement component 5 (C5 inhibitor) for the treatment of adult patients with acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG).

                          Product Name : Zilbrysq

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          November 14, 2022

                          Lead Product(s) : Zilucoplan Sodium

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank